

# Price Waterhouse Chartered Accountants LLP

## Independent auditor's report

### To the Members of Amanta Healthcare Limited

### Report on the audit of the financial statements

#### Opinion


1. We have audited the accompanying financial statements of Amanta Healthcare Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2020, and the Statement of Profit and Loss, Cash Flow Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2020, and its loss and cash flows for the year then ended.

#### Basis for opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Emphasis of Matter

4. We draw your attention to Note 42 of the financial statements, which describes the management's assessment of the impact of the outbreak of Corona virus (Covid-19) on the business operations of the Company. The management believes that no adjustments are required in the financial statements as it does not impact the current financial year, however, in view of the various preventive measures taken (such as complete lock-down restrictions by the Government of India, travel restrictions, etc.) and highly uncertain economic environment, a definitive assessment of the impact on the subsequent periods is highly dependent upon circumstances as they evolve. Our opinion is not modified in respect of this matter.



Price Waterhouse Chartered Accountants LLP, 1701, 17th Floor, Shapath V, Opp. Karnavati Club, S G Highway  
Ahmedabad - 380 051, Gujarat, India  
T: +91 (79) 3091 7000, F: +91 (79) 3091 7082

# Price Waterhouse Chartered Accountants LLP

## INDEPENDENT AUDITOR'S REPORT

To the Members of Amanta Healthcare Limited  
Report on audit of the Financial Statements  
Page 2 of 5

### Other Information

5. The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board of Director's report, but does not include the financial statements and our auditor's report thereon. The Board of Director's report is expected to be made available to us after the date of this auditor's report.


Our opinion on the financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the Board of Director's report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take appropriate action as applicable under the relevant laws and regulations

### Responsibilities of management and those charged with governance for the financial statements

6. The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
7. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.




# Price Waterhouse Chartered Accountants LLP

## INDEPENDENT AUDITOR'S REPORT

To the Members of Amanta Healthcare Limited  
Report on audit of the Financial Statements  
Page 3 of 5

### Auditor's responsibilities for the audit of the financial statements

8. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
9. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
  - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
  - Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.




# Price Waterhouse Chartered Accountants LLP

## INDEPENDENT AUDITOR'S REPORT

To the Members of Amanta Healthcare Limited  
Report on audit of the Financial Statements  
Page 4 of 5

### Report on other legal and regulatory requirements

11. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure B a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
12. As required by Section 143(3) of the Act, we report that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - (c) The Balance Sheet, the Statement of Profit and Loss and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
  - (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act.
  - (e) On the basis of the written representations received from the directors as on March 31, 2020 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2020 from being appointed as a director in terms of Section 164 (2) of the Act.
  - (f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
  - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
    - i) The Company has disclosed the impact of pending litigations on its financial position in its financial statements – Refer Note 35 to the financial statements;
    - ii) The Company has long-term contracts as at March 31, 2020 for which there were no material foreseeable losses. The Company did not have any derivative contracts as at March 31, 2020.
    - iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended March 31, 2020.
    - iv) The reporting on disclosures relating to Specified Bank Notes is not applicable to the Company for the year ended March 31, 2020.




# Price Waterhouse Chartered Accountants LLP

## INDEPENDENT AUDITOR'S REPORT

To the Members of Amanta Healthcare Limited  
Report on audit of the Financial Statements  
Page 5 of 5

13. The Company has paid/ provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.

For Price Waterhouse Chartered Accountants LLP  
Firm Registration Number: 012754N/N500016  
Chartered Accountants



Viren Shah  
Partner

Place: Ahmedabad  
Date: September 5, 2020

Membership Number: 046521  
UDIN: 20046521AAAAEV5899

# Price Waterhouse Chartered Accountants LLP

## Annexure A to Independent Auditors' Report

Referred to in paragraph 12 (f) of the Independent Auditors' Report of even date to the members of Amanta Healthcare Limited on the financial statements for the year ended March 31, 2020

Page 1 of 2

### Report on the Internal Financial Controls with reference to financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act


1. We have audited the internal financial controls with reference to financial statements of Amanta Healthcare Limited ("the Company") as of March 31, 2020 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

#### Management's Responsibility for Internal Financial Controls

2. The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

#### Auditors' Responsibility

3. Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing deemed to be prescribed under section 143(10) of the Act to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.
4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to financial statements.



# **Price Waterhouse Chartered Accountants LLP**

## **Annexure A to Independent Auditors' Report**

Referred to in paragraph 12 (f) of the Independent Auditors' Report of even date to the members of Amanta Healthcare Limited on the financial statements for the year ended March 31, 2020

Page 2 of 2

### **Meaning of Internal Financial Controls with reference to financial statements**

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.


### **Inherent Limitations of Internal Financial Controls with reference to financial statements**

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

8. In our opinion, the Company has, in all material respects, an adequate internal financial controls system with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. Also refer paragraph 4 of our main audit report.

For Price Waterhouse Chartered Accountants LLP  
Firm Registration Number: 012754N/N500016  
Chartered Accountants



Viren Shah  
Partner

Membership Number: 046521  
UDIN: 20046521AAAAEV5899

Place: Ahmedabad  
Date: September 5, 2020


## Price Waterhouse Chartered Accountants LLP

### Annexure B to Independent Auditors' Report

Referred to in paragraph 11 of the Independent Auditors' Report of even date to the members of Amanta Healthcare Limited on the financial statements as of and for the year ended March 31, 2020

- i. (a) The Company is maintaining proper records showing full particulars, including quantitative details and situation, of fixed assets.  
  
(b) The fixed assets of the Company have not been physically verified by the Management during the year, and in view of the lockdown consequent to the outbreak of Coronavirus (Covid-19), the physical verification of fixed assets could not be carried out by the Company as at the year end. However, the Company has carried out the physical verification of fixed assets subsequent to the year end; and no material discrepancies have been noticed on such verification. In our opinion, the frequency of verification is reasonable.  
  
(c) The title deeds of immovable properties, as disclosed in Note 12 on Property, plant and equipment to the financial statements, are held in the name of the Company.
- ii. The physical verification of inventory have been conducted at reasonable intervals by the Management during the year. The discrepancies noticed on physical verification of inventory as compared to book records were not material.
- iii. The Company has not granted any loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under Section 189 of the Act. Therefore, the provisions of Clause 3(iii), (iii)(a), (iii)(b) and (iii)(c) of the said Order are not applicable to the Company.
- iv. The Company has not granted any loans or made any investments, or provided any guarantees or security to the parties covered under Section 185 and 186 of the Act. Therefore, the provisions of Clause 3(iv) of the said Order are not applicable to the Company.
- v. In our opinion, and according to the information and explanations given to us, the Company has complied with the provisions of Sections 73, 74, 75 and 76 or any other relevant provisions of the Act and the Rules framed thereunder to the extent notified, with regard to the deposits accepted from the public. According to the information and explanations given to us, no order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Court or any other Tribunal on the Company in respect of the aforesaid deposits.
- vi. Pursuant to the rules made by the Central Government of India, the Company is required to maintain cost records as specified under Section 148(1) of the Act in respect of its products. We have broadly reviewed the same, and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.
- vii. (a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, the Company is generally regular in depositing undisputed statutory dues in respect of provident fund, professional tax, employees' state insurance, income tax, and goods and service tax, though there has been a slight delay in a few cases, and is regular in depositing undisputed statutory dues, including service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues, as applicable, with the appropriate authorities. Also refer Note 41 to the financial statements regarding management's assessment on certain matters relating to provident fund.

Further, for the period March 1, 2020 to March 31, 2020, the Company has paid Goods and Services Tax and filed GSTR 1 and GSTR3B (after the due date but) within the timelines allowed by the Central Board of Indirect Taxes and Customs under the Notification Number 31/2020,





## Price Waterhouse Chartered Accountants LLP

### Annexure B to Independent Auditors' Report

Referred to in paragraph 11 of the Independent Auditors' Report of even date to the members of Amanta Healthcare Limited on the financial statements for the year ended March 31, 2020


Page 2 of 3

32/2020 and 33/2020 - Central Tax dated April 3, 2020 on fulfilment of conditions specified therein.

- b) According to the information and explanations given to us and the records of the Company examined by us, there are no dues of income-tax, sales tax, duty of customs and duty of excise which have not been deposited on account of any dispute. The particulars of dues of service tax and value added tax as at March 31, 2020 which have not been deposited on account of a dispute, are as follows:

| Name of the statute | Nature of dues | Amount (Rs. in lakhs) | Period to which the amount relates | Forum where the dispute is pending                |
|---------------------|----------------|-----------------------|------------------------------------|---|
| Finance Act, 1994   | Service Tax    | 5.44                  | 2008-09                            | Custom, Excise and Service Tax Appellate Tribunal |
| Finance Act, 1994   | Service Tax    | 2.02                  | 2008-09                            | Commissioner (Appeals III)                        |

- viii. According to the records of the Company examined by us and the information and explanation given to us, the Company has not defaulted in repayment of loans or borrowings to any financial institution or bank or dues to debenture holders as at the balance sheet date. The Company did not have any outstanding loans or borrowings to any Government as at the balance sheet date.
- ix. In our opinion, and according to the information and explanations given to us, the moneys raised by way of term loans have been applied for the purposes for which they were obtained. The Company has not raised any money by way of initial public offer or further public offer (including debt instruments).
- x. During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of material fraud by the Company or on the Company by its officers or employees, noticed or reported during the year, nor have we been informed of any such case by the Management.
- xi. The Company has paid/ provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act. Also refer paragraph 13 of our main audit report.
- xii. As the Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to it, the provisions of Clause 3(xii) of the Order are not applicable to the Company.
- xiii. The Company has entered into transactions with related parties in compliance with the provisions of Section 177 and 188 of the Act. The details of such related party transactions have been disclosed in the financial statements as required under Accounting Standard (AS) 18, Related Party Disclosures specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- xiv. The Company has not made a preferential allotment/ private placement of shares/ fully or partly convertible debentures during the year under review. Accordingly, the provisions of Clause 3(xiv) of the Order are not applicable to the Company.




## Price Waterhouse Chartered Accountants LLP

### Annexure B to Independent Auditors' Report

Referred to in paragraph 11 of the Independent Auditors' Report of even date to the members of Amanta Healthcare Limited on the financial statements for the year ended March 31, 2020  
Page 3 of 3

- xv. The Company has not entered into any non-cash transactions with its directors or persons connected with him. Accordingly, the provisions of Clause 3(xv) of the Order are not applicable to the Company.
- xvi. The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, the provisions of Clause 3(xvi) of the Order are not applicable to the Company.

For Price Waterhouse Chartered Accountants LLP  
Firm Registration Number: 012754N/N500016  
Chartered Accountants



Viren Shah  
Partner

Membership Number: 046521  
UDIN: 20046521AAAAEV5899

Place: Ahmedabad  
Date: September 5, 2020

Amanta Healthcare Limited  
Balance Sheet as at 31st March, 2020

| Particulars   | Note No. | Amount (Rs. in lakhs)  |                        |
|---|----------|------------------------|------------------------|
|   |          | As at 31st March, 2020 | As at 31st March, 2019 |
| <b>Equity And Liabilities</b>   |          |                        |                        |
| <b>Shareholders' Funds</b>  |          |                        |                        |
| (a) Share capital   | 2        | 2,682.94               | 2,682.94               |
| (b) Reserves and surplus  | 3        | 226.94                 | 2,114.42               |
|   |          | <b>2,909.88</b>        | <b>4,797.36</b>        |
| <b>Non-Current Liabilities</b>  |          |                        |                        |
| (a) Long-term borrowings  | 4        | 19,244.01              | 19,576.50              |
| (b) Deferred tax liabilities (net)  | 5        | 3,848.81               | 3,826.05               |
| (c) Other long-term liabilities   | 6        | 5,026.78               | 3,249.90               |
| (d) Long-term provisions  | 7        | 407.64                 | 324.71                 |
|   |          | <b>28,527.24</b>       | <b>26,977.16</b>       |
| <b>Current Liabilities</b>  |          |                        |                        |
| (a) Short-term borrowings   | 8        | 3,421.10               | 4,191.74               |
| (b) Trade payables  |          |                        |                        |
| (i) Total outstanding dues of micro enterprises and small enterprises; and                  | 9        | 142.93                 | 249.45                 |
| (ii) Total outstanding dues of creditors other than micro enterprises and small enterprises | 9        | 1,594.57               | 1,945.09               |
| (c) Other current liabilities   | 10       | 1,832.04               | 2,047.12               |
| (d) Short-term provisions   | 11       | 339.27                 | 59.04                  |
|   |          | <b>7,329.91</b>        | <b>8,492.44</b>        |
| <b>Total</b>  |          | <b>38,767.03</b>       | <b>40,266.96</b>       |
| <b>Assets</b>   |          |                        |                        |
| <b>Non-Current Assets</b>   |          |                        |                        |
| (a) Property, plant and equipment   |          |                        |                        |
| (i) Tangible assets   | 12       | 24,198.45              | 24,427.09              |
| (ii) Intangible assets  | 12       | 191.96                 | 257.97                 |
| (iii) Capital work-in-progress  |          | -                      | 23.40                  |
| (b) Non-current investments   | 13       | 10.00                  | 10.00                  |
| (c) Long-term loans and advances  | 14       | 3,559.02               | 3,563.94               |
| (d) Other non-current assets  | 15       | 300.66                 | 526.81                 |
|   |          | <b>28,260.09</b>       | <b>28,809.21</b>       |
| <b>Current Assets</b>   |          |                        |                        |
| (a) Inventories   | 16       | 3,933.50               | 3,837.45               |
| (b) Trade receivables   | 17       | 5,227.98               | 5,222.74               |
| (c) Cash and bank balances  | 18       | 622.19                 | 1,310.24               |
| (d) Short-term loans and advances   | 19       | 368.92                 | 702.66                 |
| (e) Other current assets  | 20       | 354.35                 | 384.66                 |
|   |          | <b>10,506.94</b>       | <b>11,457.75</b>       |
| <b>Total</b>  |          | <b>38,767.03</b>       | <b>40,266.96</b>       |

See accompanying notes to the financial statements

In terms of our report of even date.

For Price Waterhouse Chartered Accountants LLP

Chartered Accountants

Firm Registration No.: 012754N/N500016

*Viren Shah*

Viren Shah

Partner

Membership No: 046521

Place: Ahmedabad

Date: 5<sup>th</sup> September, 2020

For and on behalf of Board of Directors

*Rohit J. Patel*

Rohit J. Patel

Chairman

DIN: 00088482

*Shailesh M. Shah*

Shailesh M. Shah

Chief Finance Officer

*Bhavesh G. Patel*

Bhavesh G. Patel


Managing Director

DIN: 00085505

*Shivani Thaker*

Shivani Thaker

Company Secretary



Place: Ahmedabad

Date: 5<sup>th</sup> September, 2020

Amanta Healthcare Limited  
Statement of Profit and Loss for the year ended 31st March, 2020

| Particulars   | Note No. | Amount (Rs. in lakhs)          |                                |
|---|----------|--------------------------------|--------------------------------|
|   |          | Year ended<br>31st March, 2020 | Year ended<br>31st March, 2019 |
| <b>INCOME</b>   |          |                                |                                |
| Revenue from operations   | 21       | 18,436.79                      | 18,486.65                      |
| Other income  | 22       | 213.27                         | 169.40                         |
| <b>Total Revenue</b>  |          | <b>18,650.06</b>               | <b>18,656.05</b>               |
| <b>EXPENSES</b>   |          |                                |                                |
| Cost of materials consumed  | 23       | 6,550.54                       | 6,802.68                       |
| Purchases of stock-in-trade   |          | 221.95                         | 139.58                         |
| Changes in inventories of finished goods, work-in-process and stock-in-trade            | 24       | (389.93)                       | (253.02)                       |
| Employee benefits expense   | 25       | 3,329.40                       | 3,134.38                       |
| Finance costs   | 26       | 3,812.87                       | 4,055.19                       |
| Depreciation and amortization expense   | 12       | 1,649.29                       | 1,654.38                       |
| Other expenses  | 27       | 4,987.83                       | 4,572.26                       |
| <b>Total Expenses</b>   |          | <b>20,161.95</b>               | <b>20,105.45</b>               |
| <b>Loss before tax</b>  |          | <b>(1,511.89)</b>              | <b>(1,449.40)</b>              |
| Tax Expense:  |          |                                |                                |
| Current Tax   |          | 327.10                         | 342.69                         |
| Less: MAT credit entitlement - Previous Year  |          | -                              | (8.54)                         |
| Less: Tax Adjustment in respect of Earlier Years  |          | 25.73                          | -                              |
| Deferred Tax  |          | 22.76                          | 91.04                          |
| <b>Total Tax Expenses</b>   |          | <b>375.59</b>                  | <b>425.19</b>                  |
| <b>Loss for the year</b>  |          | <b>(1,887.48)</b>              | <b>(1,874.59)</b>              |
| Earnings per Equity Share [Nominal Value per share: Rs. 10<br>(March 31, 2019: Rs. 10)] | 40       |                                |                                |
| Basic   |          | (7.04)                         | (6.99)                         |
| Diluted   |          | (7.04)                         | (6.99)                         |

See accompanying notes to the financial statements

In terms of our report of even date.

For Price Waterhouse Chartered Accountants LLP

Chartered Accountants

Firm Registration No.: 012754N/N500016

*Viren Shah*

Viren Shah

Partner

Membership No: 046521

Place: Ahmedabad

Date: 5th September, 2020



For and on behalf of Board of Directors

*Rohit J. Patel*

Rohit J. Patel

Chairman

DIN: 00088482

*Shailesh M. Shah*

Shailesh M. Shah

Chief Finance Officer

*Bhavesh G. Patel*

Bhavesh G. Patel

Managing Director

DIN: 00085505

*Shivani Thaker*

Shivani Thaker


Company Secretary

Place: Ahmedabad

Date: 5th September, 2020

Amanta Healthcare Limited  
Cash Flow Statement for the year ended 31st March, 2020

| Particulars  | Amount (Rs. in lakhs)          |                                |
|--|--------------------------------|--------------------------------|
|  | Year ended<br>31st March, 2020 | Year ended<br>31st March, 2019 |
| <b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>  |                                |                                |
| Profit before tax  | (1,511.89)                     | (1,449.40)                     |
| Adjustments for:   |                                |                                |
| Loss on sale of assets   | 9.03                           | 25.72                          |
| Unrealised foreign exchange gain   | (37.15)                        | (16.90)                        |
| Provision for doubtful trade receivables   | 29.24                          | 55.61                          |
| Bad Debts  | -                              | 1.76                           |
| Depreciation and amortization expense  | 1,649.29                       | 1,654.38                       |
| Finance costs  | 3,812.87                       | 4,055.19                       |
| Interest income  | (40.20)                        | (31.54)                        |
| Liabilities no longer required written back (net)  | (8.06)                         | (103.41)                       |
| <b>Operating Profit before Working Capital changes</b>                                   | <b>3,903.13</b>                | <b>4,191.41</b>                |
| <b>Changes in Working Capital:</b>   |                                |                                |
| Adjustments for (increase)/ decrease in operating assets:                                |                                |                                |
| Inventories  | (96.05)                        | (453.75)                       |
| Trade receivables  | 2.67                           | 130.96                         |
| Short-term loans and advances  | 333.74                         | 61.30                          |
| Long-term loans and advances   | 63.68                          | (18.19)                        |
| Other non-current assets   | 153.63                         | 158.68                         |
| Other current assets   | 34.65                          | 51.36                          |
| Adjustments for increase/ (decrease) in operating liabilities:                           |                                |                                |
| Trade payables   | (448.98)                       | (496.23)                       |
| Other current liabilities  | (45.65)                        | 227.88                         |
| Other long-term liabilities  | (5.45)                         | (2.46)                         |
| Short-term provisions  | (15.83)                        | 14.98                          |
| Long-term provisions   | 82.93                          | 17.55                          |
| <b>Cash generated from operations</b>  | <b>3,962.47</b>                | <b>3,883.50</b>                |
| Income taxes paid  | (16.09)                        | (661.57)                       |
| <b>Net cash flow from operating activities</b>   | <b>3,946.38</b>                | <b>3,221.93</b>                |
| <b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>  |                                |                                |
| Capital expenditure on property, plant and equipment including CWIP and capital advances | (1,076.30)                     | (1,978.02)                     |
| Sale of fixed assets   | 2.94                           | 1,515.08                       |
| Bank Deposits placed   | (59.55)                        | (237.79)                       |
| Proceeds from withdrawal of Bank Deposits  | 5.78                           | 201.29                         |
| Interest received  | 35.86                          | 32.21                          |
| <b>Net cash used in investing activities</b>   | <b>(1,091.27)</b>              | <b>(467.23)</b>                |
| <b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>  |                                |                                |
| Proceeds from Long-term borrowings   | 143.28                         | 218.73                         |
| Repayment of Long-term borrowings  | (1,108.77)                     | (753.93)                       |
| Net proceeds from Short-term borrowings  | (770.64)                       | (65.62)                        |
| Finance Costs paid   | (1,933.30)                     | (1,521.31)                     |
| <b>Net cash used in financing activities</b>   | <b>(3,669.43)</b>              | <b>(2,122.13)</b>              |
| <b>Net (decrease)/increase in Cash and Cash Equivalents (A+B+C)</b>                      | <b>(814.34)</b>                | <b>632.57</b>                  |
| Opening balance of Cash and Cash Equivalents   | 920.79                         | 288.22                         |
| <b>Closing balance of Cash and Cash Equivalents</b>                                      | <b>106.45</b>                  | <b>920.79</b>                  |



Amanta Healthcare Limited  
Cash Flow Statement for the year ended 31st March, 2020

Amount (Rs. in lakhs)

Note: 1 Reconciliation of cash and cash equivalents with Balance Sheet:

|  | As at<br>31st March, 2020 | As at<br>31st March, 2019 |
|--|---------------------------|---------------------------|
| Closing balance of Cash and Cash Equivalents                   | 106.45                    | 920.79                    |
| Add: Bank balances not considered as cash and cash equivalents |                           |                           |
|  | 515.74                    | 389.45                    |
| Cash and Bank Balances as per Balance Sheet (Refer Note 18)    | 622.19                    | 1,310.24                  |

Note: 2 The cash flow statement has been prepared under the "indirect method" as set out in Accounting Standard - 3 "Cash Flow Statement".


Note: 3 Cash flows from operating activities includes Rs. 94.73 lakhs (Previous year Rs. 1.37 lakhs) being expenses towards Corporate Social Responsibility initiatives. (Refer note no. 38).

Note: 4 The previous year's figures have been regrouped wherever necessary to make them comparable with current year's figures.

See accompanying notes to the financial statements

In terms of our report of even date.

For Price Waterhouse Chartered Accountants LLP  
Chartered Accountants  
Firm Registration No.: 012754N/N500016



Viren Shah  
Partner  
Membership No: 046521

Place: Ahmedabad  
Date: 5th September, 2020

For and on behalf of Board of Directors




Rohit J. Patel  
Chairman  
DIN: 00088482

Shailesh M. Shah  
Chief Finance Officer

Place: Ahmedabad  
Date: 5th September, 2020





Bhavesh G. Patel  
Managing Director  
DIN: 00085505



Shivani Thaker  
Company Secretary

Amanta Healthcare Limited  
Notes to Financial Statements


| 2 Share capital  | Amount (Rs. in lakhs)     |                           |
|--|---------------------------|---------------------------|
|  | As at<br>31st March, 2020 | As at<br>31st March, 2019 |
| <b>Authorised:</b>   |                           |                           |
| 90,150,000 (Previous year 90,150,000) Equity Shares of Rs. 10 each | 9,015.00                  | 9,015.00                  |
| <b>Issued, Subscribed and Paid-up:</b>                             |                           |                           |
| 26,829,351 (Previous year 26,829,351) Equity Shares of Rs. 10 each | 2,682.94                  | 2,682.94                  |
|  | <u>2,682.94</u>           | <u>2,682.94</u>           |

2.1 A reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period:

| Particulars                                     | As at<br>31st March, 2020 |                   | As at<br>31st March, 2019 |                   |
|---|---------------------------|-------------------|---------------------------|-------------------|
|   | Number of Shares          | Amount (in lakhs) | Number of Shares          | Amount (in lakhs) |
| Equity Share Capital                            |                           |                   |                           |                   |
| Shares outstanding at the beginning of the year | 26829351                  | 2,682.94          | 26626369                  | 2662.64           |
| Shares issued pursuant to scheme of Arrangement | -                         | -                 | 202982                    | 20.30             |
| Shares outstanding at the end of the year       | <u>26,829,351</u>         | <u>2,682.94</u>   | <u>26,829,351</u>         | <u>2,682.94</u>   |

2.2 Details of shares held by shareholders holding more than 5% of the aggregate shares in the Company:

| Particulars                        | As at<br>31st March, 2020      |               | As at<br>31st March, 2019      |               |
|------------------------------------|--------------------------------|---------------|--------------------------------|---------------|
|                                    | Number of Shares<br>(in lakhs) | %             | Number of<br>Shares (in lakhs) | %             |
| Mr. Praful J. Patel                | 44.72                          | 16.67%        | 44.72                          | 16.67%        |
| Mr. Jitendra J. Patel              | 33.76                          | 12.58%        | 33.76                          | 12.58%        |
| Mr. Bhavesh G. Patel               | 34.62                          | 12.90%        | 34.62                          | 12.90%        |
| Mr. Vishal A. Patel                | 32.84                          | 12.24%        | 32.84                          | 12.24%        |
| Milcent Appliances Private Limited | 31.00                          | 11.55%        | 31.00                          | 11.55%        |
| Mr. Pravin D. Mehta                | 28.05                          | 10.45%        | 28.05                          | 10.45%        |
| Mr. Niranjana Patel                | 17.26                          | 6.43%         | 17.26                          | 6.43%         |
|                                    | <u>222.25</u>                  | <u>82.82%</u> | <u>222.25</u>                  | <u>82.82%</u> |



2.3 Shares allotted as fully paid up pursuant to scheme of arrangement without payment being received in cash (during 5 years immediately preceding March 31, 2020):  
202,982 Equity share of Rs. 10 each has been issued on November 30, 2018 to the shareholders of Marck Remedies Private Limited pursuant to the scheme of amalgamation without payment being received in cash.

2.4 Rights, preferences and restrictions attached to Equity shares:


The Company has one class of equity shares having a par value of Rs. 10 per share. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amount, in proportion to their shareholding.

| 3 Reserves and surplus                                | As at<br>31st March, 2020 | As at<br>31st March, 2019 |
|---|---------------------------|---------------------------|
| <b>Securities Premium</b>                             |                           |                           |
| Balance as at the beginning of the year               | 7,950.77                  | 7,950.77                  |
| Less: Utilisation of Securities Premium (Note No.3.1) | (5,852.39)                | -                         |
| <b>Balance as at the end of the year</b>              | <b>2,098.38</b>           | <b>7,950.77</b>           |
| <b>General Reserve</b>                                | <b>1.44</b>               | <b>1.44</b>               |
| <b>Debenture Redemption Reserve</b>                   | <b>14.60</b>              | <b>14.60</b>              |
| <b>Surplus in the Statement of Profit and Loss</b>    |                           |                           |
| Balance as at the beginning of the year               | (5,852.39)                | (3,977.80)                |
| Add: Loss for the year                                | (1,887.48)                | (1,874.59)                |
| Add: Utilisation of Securities Premium (Note No.3.1)  | 5,852.39                  | -                         |
| <b>Balance as at the end of the year</b>              | <b>(1,887.48)</b>         | <b>(5,852.39)</b>         |
| <b>Total</b>  | <b>226.94</b>             | <b>2,114.42</b>           |

#### 3.1 Utilisation of Securities Premium

The Board at its meeting held on January 28, 2019 had approved a Scheme of Capital Reduction under section 66 of the Companies Act, 2013 read with section 52 of the Companies Act 2013 for setting off accumulated losses as per audited Financial statement as at March 31, 2019 (the Scheme) amounting to Rs.5852.39 lakhs against the Securities Premium Account. The Scheme was approved by the shareholders in the Extra ordinary General Meeting dated February 28, 2019, and was sanctioned by the National Company Law Tribunal (NCLT), Ahmedabad Bench vide order dated January 9, 2020. The order of NCLT has been filed with the Registrar of Companies, Gujarat as on February 03, 2020. The effect of such utilisation of share premium has been considered in the financial statements during the year.

| 4 Long-term borrowings   | As at<br>31st March, 2020 |          | As at<br>31st March, 2019 |            |
|--|---------------------------|----------|---------------------------|------------|
|  | Non-current               | Current  | Non-current               | Current    |
| <b>Secured</b>   |                           |          |                           |            |
| Non-Convertible Debentures   | 7,153.72                  | 42.86    | 7,153.72                  | 111.87     |
| 7324 (Previous year: 7324) Redeemable Non-Convertible Debentures of Rs. 98,260 (Previous year 99,202) each |                           |          |                           |            |
| <u>Term Loans:</u>   |                           |          |                           |            |
| From banks   | 208.09                    | 80.99    | 195.50                    | 506.25     |
| From others  | 10,893.06                 | 178.05   | 10,923.70                 | 179.85     |
|  | 11,101.15                 | 259.04   | 11,119.20                 | 686.10     |
| <b>Unsecured</b>   |                           |          |                           |            |
| <u>Term Loans:</u>   |                           |          |                           |            |
| From others  | 690.40                    | 19.69    | 707.55                    | 23.16      |
| <u>Deposits:</u>   |                           |          |                           |            |
| From members   | 298.74                    | 130.25   | 381.03                    | 263.71     |
| From related parties (Refer note no. 39)   | -                         | -        | 215.00                    | -          |
|  | 298.74                    | 130.25   | 596.03                    | 263.71     |
| Amount disclosed under the head of Other Current Liabilities (Refer note no. 10)                           | -                         | (451.84) | -                         | (1,084.84) |
|  | <b>19,244.01</b>          | <b>-</b> | <b>19,576.50</b>          | <b>-</b>   |





**Secured Debentures:**

- 4.1 The Company has issued following secured redeemable non-convertible debentures:

7,324 debentures allotted on 7th December, 2017 aggregating to Rs. 7196.58 lakhs ( Previous Year Rs. 7265.59 lakhs), carry cash coupon of 9.50% p.a. Every repayment as per repayment schedule to be done with interest rate of 14% p.a. from the date of Disbursement.

Debentures are to be redeemed as per the revised redemption schedule by 30th September, 2024 ( Previous year 31st March, 2024) and are secured by (i) first charge on pari-passu basis by equitable mortgage on factory land & building and hypothecation of plant and machineries situated at Kheda unit, both present and future and (ii) second charge on all other current assets like stock, book debts, etc. The loan is further secured by personal guarantee of promoters.

**Secured Term Loans:**

- 4.2 Term loan of Rs. Nil (Previous year : Rs. 461.91 lakhs) secured by (i) first charge on pari-passu basis by equitable mortgage on factory land & building and hypothecation of plant and machineries situated at Kheda unit, both present and future and (ii) second charge on all other current assets like stock, book debts, etc. The loan is further secured by personal guarantee of promoters. The term loan was repaid as per quarterly repayment schedule by October 2019 and carried interest rate of 6 Months Libor plus 4% p.a.

- 4.3 Term loan of Rs. 1,420.91 lakhs (Previous year : Rs. 1,420.95 lakhs) secured by (i) first charge on pari-passu basis by equitable mortgage on factory land & building and hypothecation of plant and machineries situated at Kheda unit, both present and future and (ii) second charge on all other current assets like stock, book debts, etc. The loan is further secured by personal guarantee of promoter. Loan carries cash coupon of 9.50% p.a. Every repayment as per repayment schedule to be with done Interest of 14% p.a. from the date of disbursement. This loan is repayable annually as per the revised repayment schedule by 30th September, 2024 ( Previous year 31st March, 2024).

- 4.4 Term loan of Rs. 9,642.78 lakhs (Previous year : Rs. 9,666.00 lakhs) secured by (i) first charge on pari-passu basis by equitable mortgage on factory land & building and hypothecation of plant and machineries situated at Kheda unit, both present and future and (ii) second charge on all other current assets like stock, book debts, etc. The loan is further secured by personal guarantee of promoter. Loan carries cash coupon of 4.50% p.a. Every repayment as per repayment schedule to be with done Interest of 14% p.a. from the date of disbursement. This loan is repayable annually as per the revised repayment schedule by 30th September, 2024 ( Previous year 31st March, 2024).

- 4.5 Term Loans of Rs. 296.51 lakhs (Previous year : Rs. 256.44 lakhs) is secured by hypothecation of vehicles. These are repayable in 35 to 84 monthly installments. It carries interest rate within range of 9.03% p.a. to 10.14% p.a.

**Unsecured Terms Loans:**


- 4.6 The Company has availed unsecured loan amounting to Rs. 710.09 lakhs (Previous year : Rs. 728.24 lakhs). This is repayable in 180 monthly installments. It carries interest rate of HFR plus 0.35%. One of the Director of the Company has provided his personal residential property as security to obtain the loan for the Company and director himself. The director has accepted his personal liability towards the loan by entering into a separate arrangement with the Company. The share of monthly installments including the interest thereon are regularly paid by him to the Company before they become due.

- 4.7 The Company has availed unsecured loan amounting to Rs. Nil lakhs (Previous year : Rs. 2.47 lakhs). This was repayable in 14 monthly installments. It carried interest rate 17.5 % p.a.

**Unsecured Deposits:**


- 4.8 Deposits are repayable in 6 to 36 months from the date of deposit. It carries interest from 0% p.a. to 12% p.a.

| 5 Deferred tax liabilities (Net)            | As at<br>31st March, 2020 | As at<br>31st March, 2019 |
|---|---------------------------|---------------------------|
| Deferred Tax Liability                      |                           |                           |
| Depreciation                                | 3,919.00                  | 3,818.55                  |
| Unamortised ancilliary borrowing cost       | 129.31                    | 175.51                    |
|   | 4,048.31                  | 3,994.06                  |
| Deferred Tax Assets                         |                           |                           |
| Provision for bonus                         | 8.52                      | 8.17                      |
| Provision for gratuity and leave encashment | 120.39                    | 97.77                     |
| Provision for doubtful debts                | 70.58                     | 62.07                     |
|   | 199.50                    | 168.01                    |
|   | 3,848.81                  | 3,826.05                  |




**Amanta Healthcare Limited**  
Notes to Financial Statements

|  | Amount (Rs. in lakhs) |                  |
|--|-----------------------|------------------|
|  | As at                 | As at            |
|  | 31st March, 2020      | 31st March, 2019 |
| <b>6 Other long-term liabilities</b>   |                       |                  |
| Interest accrued but not due on borrowings   | 5,026.78              | 3,244.45         |
| Employee Retention Deposits  | -                     | 5.45             |
|  | <u>5,026.78</u>       | <u>3,249.90</u>  |
| <b>7 Long-term provisions</b>  |                       |                  |
| Provision for Employee Benefits (Refer note no. 25):   |                       |                  |
| - Provision for Gratuity   | 279.89                | 218.52           |
| - Provision for Leave Encashment   | 127.75                | 106.19           |
|  | <u>407.64</u>         | <u>324.71</u>    |
| <b>8 Short-term borrowings</b>   |                       |                  |
| Secured  |                       |                  |
| Cash Credit  |                       |                  |
| From bank (Refer note 8.1 below)   | 3,364.28              | 3,944.62         |
| Unsecured  |                       |                  |
| Term Loans:  |                       |                  |
| From Banks (Refer note 8.2 below)  | -                     | 4.47             |
| Deposits:  |                       |                  |
| From members (Refer note 8.3 below)  | 56.82                 | 242.65           |
|  | <u>3,421.10</u>       | <u>4,191.74</u>  |
| 8.1 Cash credit facility from bank is secured by hypothecation of (i) entire stocks of raw materials, work-in-process, finished goods, consumables stores and spares and such other movables including trade receivables, both present and future and (ii) first charge on pari-passu basis on all fixed assets of the Kheda unit. The facility is further secured by personal guarantee of two directors. It carries interest of MCLR plus 2.00%. |                       |                  |
| 8.2 The Company has availed unsecured loan amounting to Rs. Nil lakhs (Previous year: 4.47). This was repaid in 12 monthly installments. It carried interest rate of 15.5 % p.a.   |                       |                  |
| 8.3 Deposits carries interest from 0% to 12% p.a.  |                       |                  |
| <b>9 Trade Payables</b>  |                       |                  |
|  | As at                 | As at            |
|  | 31st March, 2020      | 31st March, 2019 |
| (i) Total outstanding dues of micro and small enterprises (Refer note no. 34)  | 142.93                | 249.45           |
| (ii) Total outstanding dues of creditors other than micro and small enterprises  | 1,594.57              | 1,945.09         |
|  | <u>1,737.50</u>       | <u>2,194.54</u>  |
| <b>10 Other current liabilities</b>  |                       |                  |
|  | As at                 | As at            |
|  | 31st March, 2020      | 31st March, 2019 |
| Current maturities of long-term borrowings (Refer note no. 4)  | 451.84                | 1,084.84         |
| Interest accrued but not due on borrowings   | 230.27                | 133.06           |
| Creditors for capital goods  | 427.87                | 61.51            |
| Advances from customers  | 294.92                | 236.10           |
| Statutory dues   | 260.20                | 87.36            |
| Employee benefits payable  | 152.77                | 160.43           |
| Others*  | 14.17                 | 283.82           |
|  | <u>1,832.04</u>       | <u>2,047.12</u>  |
| * Includes remuneration payable to directors Rs. 3.46 lakhs (Previous year Rs. 3.23 lakhs)   |                       |                  |
| <b>11 Short-term provisions</b>  |                       |                  |
|  | As at                 | As at            |
|  | 31st March, 2020      | 31st March, 2019 |
| Provision for Employee Benefits (Refer note no. 25):   |                       |                  |
| - Provision for Gratuity   | -                     | 10.19            |
| - Provision for Leave Encashment   | 4.50                  | 10.14            |
|  | <u>4.50</u>           | <u>20.33</u>     |
| Other provisions:  |                       |                  |
| Provision for Income Tax (Net of Advance Tax Rs.373.25 lakhs (Previous year Rs. 688.70 lakhs)  | 334.77                | 38.71            |
|  | <u>339.27</u>         | <u>59.04</u>     |




Amanta Healthcare Limited  
Notes to Financial Statements

|  | Amount (Rs. in lakhs) |                  |
|--|-----------------------|------------------|
|  | As at                 | As at            |
|  | 31st March, 2020      | 31st March, 2019 |
| <b>13 Non-current investments</b>  |                       |                  |
| Unquoted Long-term Investments (Valued at cost)  |                       |                  |
| Investment in Mutual Funds   |                       |                  |
| 100,000 (Previous Year: 100,000) Units of SBI Dual Advantage Fund Series XXIV Regular Growth Plan of NAV of Rs. 10.45 each                 | 10.00                 | 10.00            |
| Investment in Equity shares  | -                     | -                |
| 50 Equity shares of Natpur Co-op Bank Limited of Rs. 10 each, fully paid-up  | -                     | -                |
| 1,950,000 Equity shares of SKAPS Limited of Rs 10 each, fully paid-up  | -                     | -                |
|  | <b>10.00</b>          | <b>10.00</b>     |
| <b>14 Long-term loans and advances</b>   |                       |                  |
| Unsecured, considered Good:  |                       |                  |
| Capital Advances   | 1,140.54              | 1,041.10         |
| Security Deposits  | 148.54                | 194.64           |
| Advance Income Tax [Net of Provision Rs.895.17 lakhs (Previous year Rs. 895.17 lakhs)]   | 581.90                | 250.36           |
| MAT Credit Entitlement   | 1,668.66              | 2,040.88         |
| Loans to Employees   | 19.38                 | 4.52             |
| Prepaid Expenses   | -                     | 7.40             |
| Amount paid under protest  | -                     | 25.04            |
|  | <b>3,559.02</b>       | <b>3,563.94</b>  |
| <b>15 Other non-current assets</b>   |                       |                  |
| Long term deposits with Bank with maturity period more than 12 months*   | 10.24                 | 82.76            |
| Unamortised ancillary borrowing cost   | 290.42                | 444.05           |
|  | <b>300.66</b>         | <b>526.81</b>    |
| *includes Margin money deposit Rs. 10.24 lakhs (Previous year Rs. 39.95 lakhs) with banks for opening Letter of Credit and Bank Guarantee. |                       |                  |
| <b>16 Inventories</b>  |                       |                  |
| (At lower of cost and net realisable value)  |                       |                  |
| Raw materials  | 846.20                | 1,224.81         |
| Packing materials  | 350.80                | 266.07           |
| Work-in-process  | 560.70                | 258.95           |
| Finished goods   | 2,088.95              | 1,949.68         |
| Finished goods in transit  | 63.97                 | 104.48           |
| Stock-in-trade   | 22.88                 | 33.46            |
|  | <b>3,933.50</b>       | <b>3,837.45</b>  |
| <b>17 Trade receivables</b>  |                       |                  |
| Unsecured:   |                       |                  |
| Outstanding for the period exceeding six months from the date they were due for payment  |                       |                  |
| - Considered good  | 1,479.52              | 1,214.90         |
| - Considered doubtful  | 242.39                | 213.15           |
| Less: Provision for doubtful debts   | (242.39)              | (213.15)         |
|  | 1,479.52              | 1,214.90         |
| Others, considered good  | 3,748.46              | 4,007.84         |
|  | <b>5,227.98</b>       | <b>5,222.74</b>  |



Amanta Healthcare Limited  
Notes to Financial Statements

|  | Amount (Rs. in lakhs) |                  |
|--|-----------------------|------------------|
|  | As at                 | As at            |
|  | 31st March, 2020      | 31st March, 2019 |
| <b>18 Cash and bank balances</b>   |                       |                  |
| Cash and cash equivalents  |                       |                  |
| - Cash on hand   | 23.03                 | 13.76            |
| - Cheques on hand  | -                     | 102.70           |
| - Balances with banks:   |                       |                  |
| in Current Accounts  | 83.42                 | 804.33           |
|  | 106.45                | 920.79           |
| <b>Other bank balances</b>   |                       |                  |
| Deposits with maturity more than 3 months but less than 12 months*   | 515.74                | 389.45           |
|  | <u>622.19</u>         | <u>1,310.24</u>  |
| *includes Margin money deposit Rs. 444.13 lakhs (Previous year Rs. 386.02 lakhs) with banks for opening Letter of Credit and Bank Guarantee. |                       |                  |
| <b>19 Short-term loans and advances</b>  |                       |                  |
|  | As at                 | As at            |
|  | 31st March, 2020      | 31st March, 2019 |
| <u>Unsecured, Considered Good</u>  |                       |                  |
| Balances with Government Authorities   | 211.14                | 565.29           |
| Loans to Employees   | 1.27                  | 3.43             |
| Advances to Employees  | 1.16                  | 30.94            |
| Prepaid Expenses   | 47.60                 | 36.29            |
| Advance to Trade creditors   | 104.70                | 63.40            |
| Others   | 3.05                  | 3.31             |
|  | <u>368.92</u>         | <u>702.66</u>    |
| <b>20 Other current assets</b>   |                       |                  |
|  | As at                 | As at            |
|  | 31st March, 2020      | 31st March, 2019 |
| Export Benefits Receivables  | 188.14                | 217.75           |
| Interest accrued on deposits with banks  | 12.58                 | 8.24             |
| Unamortised ancillary borrowing cost   | 153.63                | 158.67           |
|  | <u>354.35</u>         | <u>384.66</u>    |



**Amount (Rs. in lakhs)**

[illegible]

Amanta Healthcare Limited  
Notes to Financial Statements

12 Property, plant and equipment


Amount (Rs. in lakhs)

| Particulars                   | Gross Block              |                 |                 |                           | Depreciation/Amortisation |                 |               | Net Block                |                           |
|-------------------------------|--------------------------|-----------------|-----------------|---------------------------|---------------------------|-----------------|---------------|--------------------------|---------------------------|
|                               | As at<br>1st April, 2018 | Addition        | Disposal        | As at<br>31st March, 2019 | Upto<br>1st April, 2018   | For the Year    | Disposals     | Upto<br>31st March, 2019 | As at<br>31st March, 2019 |
| <b>12.1 Tangible Assets</b>   |                          |                 |                 |                           |                           |                 |               |                          |                           |
| Freehold Land                 | 81.74                    | -               | -               | 81.74                     | -                         | -               | -             | -                        | 81.74                     |
| Buildings                     | 6,745.35                 | 46.67           | 1,562.55        | 5,229.47                  | 1,774.70                  | 203.48          | 339.27        | 1,638.91                 | 3,590.56                  |
| Plant and Equipments          | 28,699.31                | 934.72          | 443.64          | 29,190.39                 | 8,909.10                  | 1,106.10        | 131.78        | 9,883.42                 | 19,306.97                 |
| Electric Installations        | 2,069.51                 | 32.34           | -               | 2,101.85                  | 913.94                    | 164.12          | -             | 1,078.06                 | 1,023.79                  |
| Furniture and Fixtures        | 397.38                   | 1.03            | -               | 398.41                    | 272.47                    | 22.51           | -             | 294.98                   | 103.43                    |
| Office Equipments             | 348.57                   | 13.42           | 0.41            | 361.58                    | 258.87                    | 24.12           | 0.39          | 282.60                   | 78.98                     |
| Vehicles                      | 385.42                   | 166.06          | 134.53          | 416.95                    | 260.33                    | 43.89           | 128.89        | 175.33                   | 241.62                    |
| <b>Total</b>                  | <b>38,727.28</b>         | <b>1,194.24</b> | <b>2,141.13</b> | <b>37,780.39</b>          | <b>12,389.41</b>          | <b>1,564.22</b> | <b>600.33</b> | <b>13,353.30</b>         | <b>24,427.09</b>          |
| <b>12.2 Intangible Assets</b> |                          |                 |                 |                           |                           |                 |               |                          |                           |
| Computer Software             | 72.19                    | -               | -               | 72.19                     | 62.27                     | 5.61            | -             | 67.88                    | 4.31                      |
| Goodwill                      | 422.76                   | -               | -               | 422.76                    | 84.55                     | 84.55           | -             | 169.10                   | 253.66                    |
| <b>Total</b>                  | <b>494.95</b>            | <b>-</b>        | <b>-</b>        | <b>494.95</b>             | <b>146.82</b>             | <b>90.16</b>    | <b>-</b>      | <b>236.98</b>            | <b>257.97</b>             |



**Amanta Healthcare Limited**  
**Notes to Financial Statements**

|  |   | Amount (Rs. in lakhs) |                  |                 |             |
|--|---|-----------------------|------------------|-----------------|-------------|
| 21   | Revenue from operations   | 2019-20               | 2018-19          |                 |             |
|  | Sale of Products  | 18,233.15             | 18,235.72        |                 |             |
|  | Sale of Services  | 4.68                  | 7.75             |                 |             |
|  | Other Operating Revenue:  |                       |                  |                 |             |
|  | Scrap sales   | 42.34                 | 47.35            |                 |             |
|  | Export Incentives   | 156.62                | 195.83           |                 |             |
|  |   | <u>18,436.79</u>      | <u>18,486.65</u> |                 |             |
|  | Note - Sale of products comprises sale of finished goods classified as under: |                       |                  |                 |             |
|  | Large Volume Parenterals  | 13,411.07             | 13,398.27        |                 |             |
|  | Small Volume Parenterals  | 4,680.15              | 4,657.15         |                 |             |
|  | Others  | 141.93                | 180.30           |                 |             |
|  |   | <u>18,233.15</u>      | <u>18,235.72</u> |                 |             |
| 22   | Other income  | 2019-20               | 2018-19          |                 |             |
|  | Interest Income (Refer note below)  | 40.20                 | 31.54            |                 |             |
|  | Net gain on foreign currency transactions & translation                       | 155.97                | 26.71            |                 |             |
|  | Insurance claims received   | 8.91                  | 7.18             |                 |             |
|  | Liabilities written back to the extent no longer required                     | 8.06                  | 103.41           |                 |             |
|  | Miscellaneous income  | 0.13                  | 0.56             |                 |             |
|  |   | <u>213.27</u>         | <u>169.40</u>    |                 |             |
|  | Note - Interest income comprises of:  |                       |                  |                 |             |
|  | - Interest on deposits with banks   | 34.30                 | 27.19            |                 |             |
|  | - Others  | 5.90                  | 4.35             |                 |             |
|  |   | <u>40.20</u>          | <u>31.54</u>     |                 |             |
| 23   | Cost of materials consumed  | 2019-20               | 2018-19          |                 |             |
|  | Raw Material  | 3,965.65              | 4,214.86         |                 |             |
|  | Packing Material  | 2,584.89              | 2,587.82         |                 |             |
|  |   | <u>6,550.54</u>       | <u>6,802.68</u>  |                 |             |
|  | (a) Details of material consumed:   |                       |                  |                 |             |
|  | Plastic   | 3,143.40              | 3,380.49         |                 |             |
|  | Dextrose  | 319.90                | 297.88           |                 |             |
|  | Others  | 3,087.24              | 3,124.31         |                 |             |
|  | Total   | <u>6,550.54</u>       | <u>6,802.68</u>  |                 |             |
|  | (b) Value of imported and indigenous materials consumed:                      |                       |                  |                 |             |
|  |   | 2019-20               | 2018-19          |                 |             |
| Particulars                                |   | Rs. In lakhs          | %                | Rs. In lakhs    | %           |
| Raw Materials (including packing material) |   |                       |                  |                 |             |
| Imported                                   |   | 3,181.25              | 48.56%           | 3,380.94        | 49.70%      |
| Indigenous                                 |   | 3,369.29              | 51.44%           | 3,421.74        | 50.30%      |
|  |   | <u>6,550.54</u>       | <u>100%</u>      | <u>6,802.68</u> | <u>100%</u> |



|   | Amount (Rs. in lakhs) |                 |
|---|-----------------------|-----------------|
| 24 Changes in inventories of finished goods, work-in-process and stock-in-trade | 2019-20               | 2018-19         |
| Opening Balance   |                       |                 |
| Finished goods  | 2,054.16              | 1,854.05        |
| Work-in-process   | 258.95                | 238.18          |
| Stock-in-trade  | 33.46                 | 1.32            |
|   | <u>2,346.57</u>       | <u>2,093.55</u> |
| Less: Closing Balance   |                       |                 |
| Finished goods  | 2,152.92              | 2,054.16        |
| Work-in-process   | 560.70                | 258.95          |
| Stock-in-trade  | 22.88                 | 33.46           |
|   | <u>2,736.50</u>       | <u>2,346.57</u> |
| Net increase in inventories   | <u>(389.93)</u>       | <u>(253.02)</u> |

| 25 Employee benefits expense                                     | 2019-20         | 2018-19         |
|--|-----------------|-----------------|
| Salaries and Wages   | 3,105.57        | 2,957.76        |
| Contribution to Provident and Other Funds (Refer note (a) below) | 127.43          | 86.17           |
| Gratuity (Refer note (b) below)                                  | 63.17           | 34.29           |
| Staff Welfare Expenses   | 33.23           | 56.16           |
|  | <u>3,329.40</u> | <u>3,134.38</u> |

**(a) Defined Contribution Plans**

Amount recognised in the Statement of Profit and loss

|  |               |              |
|--|---------------|--------------|
| (i) Contribution to Provident fund       | 67.38         | 41.05        |
| (ii) Contribution to Pension fund        | 58.40         | 43.15        |
| (iii) Contribution to ESI                | 1.20          | 1.69         |
| (iv) Contribution to Labour welfare fund | 0.45          | 0.28         |
| Total                                    | <u>127.43</u> | <u>86.17</u> |

**(b) Defined Benefit Plans**

The Company has a funded defined benefit gratuity plan. Every employee is entitled to a benefit equivalent to fifteen days salary last drawn for each completed year of service. The same is payable at the time of separation from the Company or retirement, whichever is earlier. The fund is managed by Life Insurance Corporation of India. Following are the further particulars with respect to gratuity for the year ended March 31, 2020.

**Gratuity:**


| Present value of the Defined Benefit obligation: |               |               |
|--|---------------|---------------|
| Particulars                                      | 2019-20       | 2018-19       |
| Obligation at the beginning of the year          | 246.00        | 220.18        |
| Current service cost                             | 28.99         | 22.91         |
| Interest cost                                    | 17.96         | 16.73         |
| Actuarial loss/(gain)                            | 17.48         | (4.10)        |
| Benefits paid                                    | (11.97)       | (9.72)        |
| Obligation at the end of the year                | <u>298.46</u> | <u>246.00</u> |

**Fair Value of Plan Assets**

| Particulars  | 2019-20      | 2018-19      |
|--|--------------|--------------|
| Fair value of plan assets at the beginning of the year | 17.29        | 16.04        |
| Expected return on plan assets                         | 1.26         | 1.22         |
| Actuarial gain/(loss)                                  | -            | 0.03         |
| Contributions by employer                              | 11.97        | 9.72         |
| Benefits paid  | (11.97)      | (9.72)       |
| Fair value of plan assets at the end of the year       | <u>18.55</u> | <u>17.29</u> |

**Expense recognised in Statement of Profit & Loss**

| Particulars                    | 2019-20      | 2018-19      |
|--------------------------------|--------------|--------------|
| Current service cost           | 28.99        | 22.91        |
| Interest cost                  | 17.96        | 16.73        |
| Expected return on plan assets | (1.26)       | (1.22)       |
| Net actuarial losses/(gains)   | 17.48        | (4.13)       |
| Total Expenses                 | <u>63.17</u> | <u>34.29</u> |





Amount (Rs. in lakhs)

**Assets & Liabilities recognised in the Balance Sheet**

| Particulars   | 2019-20  | 2018-19  |
|---|----------|----------|
| Present value of Defined Benefit obligations        | (298.46) | (246.00) |
| Fair Value of plan assets as at the end of the year | 18.55    | 17.29    |
| Amount recognised as liability                      | (279.91) | (228.71) |
| Long-term provision (Refer note no. 7)              | 279.89   | 218.52   |
| Short-term provision (Refer note no. 11)            | -        | 10.19    |
|   | 279.89   | 228.71   |

**Percentage Break-down of Total Plan Assets**

| Particulars  | 2019-20 | 2018-19 |
|--|---------|---------|
| Insurer Managed Funds (Traditional, Non Market Linked) | 100%    | 100%    |

**Actuarial assumptions**

| Particulars                            | 2019-20 | 2018-19 |
|--|---------|---------|
| Discount Rate                          | 6.50%   | 7.30%   |
| Expected rate of return on plan assets | 7.30%   | 7.60%   |
| Salary growth rate                     | 5.50%   | 5.50%   |

**Withdrawal rates :**

- 2019-20

Upto 35 years - 5% p.a and beyond 35 years - 2% p.a

- 2018-19

Upto 35 years - 5% p.a and beyond 35 years - 2% p.a

Actuarial valuation method used is Projected Unit Credit Method

**Amounts recognised in Current year and previous four years**

|   | 2019-20  | 2018-19  | 2017-18  | 2016-17  | 2015-16  |
|---|----------|----------|----------|----------|----------|
| Defined Benefit Obligation at end of the year | (298.46) | (246.00) | (220.18) | (184.53) | (161.84) |
| Fair value of plan assets at end of the year  | 18.55    | 17.29    | 16.04    | 14.90    | 13.76    |
| Surplus/(Deficit)                             | (279.91) | (228.71) | (204.14) | (169.63) | (148.08) |
| Experience adjustment in plan liabilities     | 1.06     | (9.34)   | 0.51     | (7.41)   | 10.36    |
| Experience adjustment in plan assets          | (0.05)   | 0.15     | 0.01     | 0.04     | (0.08)   |

Expected gratuity contribution for the next year is Rs. 10 lakhs (Previous year : Rs. 30 lakhs)

**(c) Other Long-term Employment Benefit**


This includes Compensated absences. The amount charged to the Statement of Profit and Loss for the year is Rs. 72.67 lakhs (Previous year: Rs. 55.65 lakhs). The actuarial liability for compensated absences for the year ended March 31, 2020 :

| Particulars                              | 2019-20 | 2018-19 |
|--|---------|---------|
| Long-term provision (Refer note no. 7)   | 127.75  | 106.19  |
| Short-term provision (Refer note no. 11) | 4.50    | 10.14   |
|  | 132.25  | 116.33  |

**26 Finance costs**

|                        | 2019-20  | 2018-19  |
|------------------------|----------|----------|
| Interest Expense       | 3,535.71 | 3,736.93 |
| Interest on Income Tax | -        | 3.80     |
| Other Borrowing Costs* | 277.16   | 314.46   |
|                        | 3,812.87 | 4,055.19 |

\*includes amortisation of ancillary borrowing cost.




Amanta Healthcare Limited  
Notes to Financial Statements

| 27 Other expenses  | Amount (Rs. in lakhs) |                 |
|--|-----------------------|-----------------|
|  | 2019-20               | 2018-19         |
| Consumption of Stores and Spare parts (Refer note below) | 319.86                | 313.67          |
| Power and Fuel   | 1,835.96              | 1,556.84        |
| Laboratory Goods and Testing Expenses                    | 109.33                | 140.36          |
| Repairs to Buildings                                     | 21.84                 | 52.98           |
| Repairs to Machinery                                     | 51.27                 | 56.51           |
| Repairs to Others  | 33.91                 | 56.37           |
| Communication Expenses                                   | 21.15                 | 24.22           |
| Legal and Professional Expenses                          | 102.73                | 81.83           |
| Printing and Stationery Expenses                         | 31.55                 | 35.82           |
| Rent   | 158.20                | 218.54          |
| Rates and Taxes  | 132.23                | 52.97           |
| Insurance  | 49.47                 | 36.58           |
| Security Service Charges                                 | 43.89                 | 54.70           |
| Travelling and Conveyance Expenses                       | 243.55                | 267.55          |
| Payment to Auditors                                      |                       |                 |
| As auditors:   |                       |                 |
| Statutory Audit  | 11.00                 | 18.50           |
| Certification  | 1.00                  | 0.50            |
| In respect of other audit services:                      |                       |                 |
| Tax Audit  | 2.50                  | 5.00            |
| Other  | -                     | 1.00            |
| Reimbursement of Expenses                                | -                     | 0.04            |
| Vehicle Running and Maintenance                          | 84.26                 | 111.85          |
| Bad Debts  | -                     | 24.15           |
| Less: Withdrawal from provision for doubtful debts       | -                     | 22.39           |
| Provision for doubtful trade receivables                 | 29.24                 | 55.61           |
|  | 29.24                 | 57.37           |
| Loss on sale of assets (net)                             | 9.03                  | 25.72           |
| Corporate Social Responsibility (Refer note 38)          | 94.73                 | 1.37            |
| Freight and Forwarding Expenses                          | 1,365.55              | 1,128.50        |
| General Expenses   | 235.58                | 273.47          |
|  | <u>4,987.83</u>       | <u>4,572.26</u> |

Note: Value of imported and indigenous materials consumed

| Particulars                        | 2019-20         |             | 2018-19         |             |
|------------------------------------|-----------------|-------------|-----------------|-------------|
|                                    | Rs. in lakhs    | %           | Rs. in lakhs    | %           |
| Stores and Spares                  |                 |             |                 |             |
| Imported                           | 16.90           | 5.28%       | 7.84            | 2.50%       |
| Indigenous                         | 302.96          | 94.72%      | 305.83          | 97.50%      |
|                                    | <u>319.86</u>   | <u>100%</u> | <u>313.67</u>   | <u>100%</u> |
| 28 CIF Value of Imports            |                 |             |                 |             |
| Raw Materials                      | 2,439.12        |             | 3,216.58        |             |
| Stores and Spares                  | 13.09           |             | 7.84            |             |
|                                    | <u>2,452.21</u> |             | <u>3,224.42</u> |             |
| 29 Expenditure in foreign currency |                 |             |                 |             |
| Foreign Travelling Expenses        | 5.67            |             | 9.47            |             |
| Other expenses                     | 53.99           |             | 37.25           |             |
|                                    | <u>59.66</u>    |             | <u>46.72</u>    |             |
| 30 Earnings in foreign currency    |                 |             |                 |             |
| FOB Value of Exports               | 4,589.43        |             | 4,337.08        |             |
|                                    | <u>4,589.43</u> |             | <u>4,337.08</u> |             |



| 31 Unhedged foreign currency exposure                    | Amount (Rs. in lakhs)             |                          |                                   |                          |
|--|-----------------------------------|--------------------------|-----------------------------------|--------------------------|
|  | 2019-20                           |                          | 2018-19                           |                          |
|  | Foreign<br>Currency (In<br>lakhs) | Amount (Rs. in<br>lakhs) | Foreign<br>Currency (In<br>lakhs) | Amount (Rs. in<br>lakhs) |
| <b>Trade receivables</b>                                 |                                   |                          |                                   |                          |
| AUD*   | 0.92                              | 42.02                    | 0.92                              | 45.02                    |
| GBP  | 2.14                              | 197.67                   | 5.53                              | 499.28                   |
| USD  | 7.71                              | 576.08                   | 4.89                              | 339.08                   |
|  |                                   | <u>815.77</u>            |                                   | <u>883.38</u>            |
| *Amount of AUD 91,569.35 (Previous year : AUD 91,569.35) |                                   |                          |                                   |                          |
| <b>Loan payable</b>                                      |                                   |                          |                                   |                          |
| USD  | -                                 | -                        | 6.71                              | 464.61                   |
|  |                                   | <u>-</u>                 |                                   | <u>464.61</u>            |
| <b>Cash/bank balance</b>                                 |                                   |                          |                                   |                          |
| USD  | 0.04                              | 2.77                     | 0.01                              | 0.49                     |
| GBP@   | 0.00                              | 0.37                     | 0.00                              | 0.37                     |
| EUR#   | 0.00                              | 0.23                     | 0.00                              | 0.02                     |
| Others**   | 0.01                              | 0.86                     | 0.01                              | 0.55                     |
|  |                                   | <u>4.23</u>              |                                   | <u>1.43</u>              |
| @Amount of GBP 405 (Previous year : GBP 405)             |                                   |                          |                                   |                          |
| #Amount of EUR 274.05 (Previous year : EUR 24.15)        |                                   |                          |                                   |                          |
| **includes multiple foreign currencies on hand           |                                   |                          |                                   |                          |

**32 Capital commitments**

Estimated amount of contracts remaining to be executed and not provided for (net of advances): Rs. 277.16 lakhs (Previous year: Rs. 13.32 lakhs)


**33 Other commitments**

The Company has imported certain goods at concessional rate of custom duty under "Advance License Scheme" of the Central Government. The Company has undertaken an incremental export obligation to the extent of US \$ 1.7 lakhs (Previous year US \$ 1.28 lakhs) equivalent to Rs. 124.65 lakhs (Previous year Rs. 90.82 lakhs) to be fulfilled during a specified period as applicable from the date of imports. The unprovided liability towards custom duty payable on unfulfilled export obligations is Rs. 7.42 lakhs (Previous year Rs. 6.95 lakhs).

**34 The Company has certain dues payable to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act'). The disclosures pursuant to the said MSMED Act are as follows: (Refer note 9)**

|  | 2019-20 | 2018-19 |
|--|---------|---------|
| Principal amount outstanding to suppliers registered under the MSMED Act and remaining unpaid as at year end                                   | 138.76  | 240.57  |
| Interest due on above principal amount payable to suppliers registered under the MSMED Act and remaining unpaid as at year end                 | 4.17    | 8.88    |
| Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year                                   | -       | -       |
| Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year            | -       | (8.88)  |
| Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year | -       | -       |
| Interest due and payable towards suppliers registered under MSMED Act, for payments already made   | -       | -       |
| Interest accrued and remaining unpaid at the end of each accounting year   | -       | -       |
| Further interest remaining due and payable for earlier years   | -       | -       |

Note: The above information regarding dues payable to Micro and Small enterprises is complied by management to the extent the information is available with the Company regarding the status of suppliers as Micro and Small enterprises.



Amount (Rs. in lakhs)

|  |         |         |
|--|---------|---------|
| <b>35 Contingent liabilities</b>                                     |         |         |
| Contingent liabilities not provided for in respect of:               |         |         |
| Particulars  | 2019-20 | 2018-19 |
| Claim against company not acknowledged as debt:                      |         |         |
| Sales tax liability for matters pending in appeals                   | -       | 185.76  |
| Service tax liability for matters pending in appeals                 | 7.46    | 7.46    |
| Liability towards arbitration order for matter pending in High court | 24.17   | 24.17   |

**36 Segment reporting**

a) Primary segment:

In accordance with the requirements of Accounting Standard 17 - "Segment Reporting" the Company has determined its business segment as Manufacturing and sale of pharmaceutical products. Since 100% of the Company's business is from Manufacturing and sale of pharmaceutical products, there are no other reportable segments. Thus the segment revenue, segment result, total carrying amount of segment assets, total carrying amount of segment liabilities, total cost incurred to acquired segments assets, the total amount of charge for depreciation and amortisation during the year are all as reflected in the financial statements for the year ended 31st March, 2020 and as on that date.

b) Secondary segments (By geography):

| Particulars  | For the year ended 31st March, 2020 |                |                | For the year ended 31st March, 2019 |                |                |
|--|-------------------------------------|----------------|----------------|-------------------------------------|----------------|----------------|
|  | India                               | Outside India  | Total          | India                               | Outside India  | Total          |
|  | Rs. (in lakhs)                      | Rs. (in lakhs) | Rs. (in lakhs) | Rs. (in lakhs)                      | Rs. (in lakhs) | Rs. (in lakhs) |
| Revenue From Customers                                   | 13,155.85                           | 5,081.98       | 18,237.83      | 13,424.37                           | 4,819.10       | 18,243.47      |
| Carrying Amount of Segment Assets                        | 37,951.26                           | 815.77         | 38,767.03      | 39,383.58                           | 883.38         | 40,266.96      |
| Addition to Property Plant and equipment during the year | 1,099.70                            | -              | 1,099.70       | 2,152.46                            | -              | 2,152.46       |

**37 Operating leases**

The Company has taken office premises and godowns on operating lease for which lease payments recognised in the Statement of profit and loss for the year is Rs. 158.20 lakhs (Previous year Rs. 218.54 lakhs).


|   |               |               |
|---|---------------|---------------|
|   | 2019-20       | 2018-19       |
| The total future minimum lease payments under non-cancellable lease are as below: |               |               |
| Not later than 1 Year   | 56.62         | 53.92         |
| Later than 1 Year and not later than 5 Years                                      | 100.20        | 156.82        |
|   | <u>156.82</u> | <u>210.74</u> |

**38 Corporate social responsibility expenditure**

- a As per section 135 of the Companies Act, 2013, the Company is not required to spend on CSR during the year ended March 31, 2020. Amount spend on CSR during the year represents amounts required to be spend as per Section 135 of the Companies Act, 2013 in respect of earlier years. The Gross amount required to be spent by the Company during the year ended March 31, 2019 was Rs. 35.12 lakhs.

- b Amount spent during the year on :

| Particulars                                | In cash | Yet to be paid in cash | Total |
|--|---------|------------------------|-------|
| (i) Construction/acquisition of any assets | -       | -                      | -     |
| (ii) On purposes other than (i) above      | 94.73   | -                      | 94.73 |



|  |              | Amount (Rs. in lakhs) |            |
|--|--------------|-----------------------|------------|
| 40 Earnings per share  |              | 2019-20               | 2018-19    |
| Weighted average no. of equity shares at the end of the year | Nos. (lakhs) | 268.29                | 268.29     |
| Loss for the year  | Rs. (lakhs)  | (1,887.48)            | (1,874.59) |
| Basic and Diluted loss per share                             | Rs.          | (7.04)                | (6.99)     |
| Nominal value of equity share                                | Rs.          | 10                    | 10         |

41 The Company has valued the impact of the recent Supreme Court Judgment in case of "Vivekananda Vidyamandir And Others Vs The Regional Provident Fund Commissioner (II) West Bengal" and the related circular (Circular No. C-1/1(33)2019/ Vivekananda Vidya Mandir/284) dated March 20, 2019 issued by the Employees' Provident Fund Organisation in relation to nonexclusion of certain allowances from the definition of "basic wages" of the relevant employees for the purposes of determining contribution to provident fund under the Employees' Provident Funds & Miscellaneous Provisions Act, 1952. The amount of additional liability, if any, is recoverable from the employees as per the employment contracts. Accordingly, in the assessment of the management, the aforesaid matter is not likely to have a material impact on the financial statement of the Company.

42 Impact due to Covid-19 pandemic

Consequent to the nationwide lockdown announced by the Government of India, the Company's plant and offices were shut down from March 25, 2020 onwards. Since the Company is in the business of manufacturing essential goods (Pharmaceutical products), the Company was able to resume its operations from March 29, 2020 in accordance with the various directives of the Government. Except for sub-optimal utilization of plant capacity due to unavailability of workers during the initial 3 weeks of lockdown, the Company's operations have not been affected due to the Covid-19 pandemic. The COVID-19 crisis has caused significant disturbance and slowdown of economic activity. The Company's Management has done an assessment of the situation, including the liquidity position and the recoverability and carrying value of all its assets and liabilities as at March 31, 2020, and concluded that there are no material adjustments required in the financial statements as of March 31, 2020. However, the impact assessment of COVID-19 is a continuing process given the uncertainty associated with its nature and duration. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of these financial statements. The Company will continue to monitor any material changes as the situation evolves.

43 The previous year figures have been regrouped/re-classified to conform to the current year's classification.

In terms of our report of even date.

For Price Waterhouse Chartered Accountants LLP

Chartered Accountants

Firm Registration No.: 012754N/N500016

*Viren Shah*

Viren Shah

Partner

Membership No: 046521

Place: Ahmedabad

Date: 5th September, 2020

For and on behalf of Board of Directors

*Rohit J. Patel*

Rohit J. Patel

Chairman

DIN: 00088482

*Shailesh M. Shah*

Shailesh M. Shah

Chief Finance Officer

*Bhavesh G. Patel*

Bhavesh G. Patel

Managing Director

DIN: 00085505

*Shivani Thaker*

Shivani Thaker


Company Secretary



Place: Ahmedabad

Date: 5th September, 2020

|  |  |                          |         |                                      |         |            |         |   |         |         |         |
|--|--|--------------------------|---------|--------------------------------------|---------|------------|---------|---|---------|---------|---------|
| 39 Related Party Disclosures   |  |                          |         |                                      |         |            |         |   |         |         |         |
| (a) Names of related parties and nature of relationship:                       |  |                          |         |                                      |         |            |         |   |         |         |         |
| Other Related Parties with whom transactions have taken place during the year: |  |                          |         |                                      |         |            |         |   |         |         |         |
| Nature of Relationship   |  | Name of related parties  |         |                                      |         |            |         |   |         |         |         |
| Key Management Personnel   |  | Bhavesh G. Patel         |         |                                      |         |            |         |   |         |         |         |
|  |  | Rohit J. Patel           |         |                                      |         |            |         |   |         |         |         |
| Relatives of Key Management Personnel  |  | Chirag K. Desai          |         |                                      |         |            |         |   |         |         |         |
|  |  | Gargi R. Patel           |         |                                      |         |            |         |   |         |         |         |
|  |  | Jayshreen Patel          |         |                                      |         |            |         |   |         |         |         |
|  |  |                          |         |                                      |         |            |         |   |         |         |         |
| (b) Transactions with related parties  |  |                          |         |                                      |         |            |         |   |         |         |         |
|  |  | Key Management Personnel |         | Relative of Key Management Personnel |         | Associates |         | Enterprise over which KMP is able to exercise significant influence                 |         | Total   |         |
|  |  | 2019-20                  | 2018-19 | 2019-20                              | 2018-19 | 2019-20    | 2018-19 | 2019-20   | 2018-19 | 2019-20 | 2018-19 |
| Managerial Remuneration  |  |                          |         |                                      |         |            |         |   |         |         |         |
| Bhavesh G. Patel   |  | 75.22                    | 52.93   | -                                    | -       | -          | -       | -   | -       | 75.22   | 52.93   |
| Public Deposit accepted/renewed during the year                                |  |                          |         |                                      |         |            |         |   |         |         |         |
| Rohit J. Patel   |  | -                        | 115.00  | -                                    | -       | -          | -       | -   | -       | -       | 115.00  |
| Jayshree R. Patel  |  | -                        | -       | -                                    | 50.00   | -          | -       | -   | -       | -       | 50.00   |
| Gargiben R. Patel  |  | -                        | -       | -                                    | 50.00   | -          | -       | -   | -       | -       | 50.00   |
| Public Deposit matured during the year   |  |                          |         |                                      |         |            |         |   |         |         |         |
| Rohit J. Patel   |  | 115.00                   | 170.00  | -                                    | -       | -          | -       | -   | -       | 115.00  | 170.00  |
| Jayshree R. Patel  |  | -                        | 50.00   | 70.00                                | -       | -          | -       | -   | -       | 50.00   | 70.00   |
| Gargiben R. Patel  |  | -                        | -       | 50.00                                | 50.00   | -          | -       | -   | -       | 50.00   | 50.00   |
| (c) Balances outstanding as on 31st March 2020                                 |  |                          |         |                                      |         |            |         |   |         |         |         |
|  |  | Key Management Personnel |         | Relative of Key Management Personnel |         | Associates |         | Enterprise over which the relative of KMP is able to exercise significant influence |         | Total   |         |
|  |  | 2019-20                  | 2018-19 | 2019-20                              | 2018-19 | 2019-20    | 2018-19 | 2019-20   | 2018-19 | 2019-20 | 2018-19 |
| Receivables  |  |                          |         |                                      |         |            |         |   |         |         |         |
| Balance Payable at the year end  |  |                          |         |                                      |         |            |         |   |         |         |         |
| Rohit J. Patel   |  | -                        | 115.00  | -                                    | -       | -          | -       | -   | -       | -       | 115.00  |
| Bhavesh G. Patel   |  | 3.46                     | 3.23    | -                                    | -       | -          | -       | -   | -       | 3.46    | 3.23    |
| Gargi R. Patel   |  | -                        | -       | -                                    | 50.00   | -          | -       | -   | -       | -       | 50.00   |
| Jayshreen Patel  |  | -                        | -       | -                                    | 50.00   | -          | -       | -   | -       | -       | 50.00   |
| Chirag K. Desai  |  | -                        | -       | -                                    | 280.58  | -          | -       | -   | -       | -       | 280.58  |



**AMANTA HEALTHCARE LIMITED**  
**Notes to Financial Statements**

**Corporate Information:**

M/s Amanta Healthcare Limited ('the Company') is a sterile liquid pharmaceutical products manufacturing and formulation development Company having head quarter at Ahmedabad, Gujarat, India. It has manufacturing facilities in the state of Gujarat. The Company manufactures Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs). The technology deployed for manufacturing is Blow Fill Seal (BFS), Injection Stretch Blow Molding (ISBM) and conventional three Piece line. The product group comprises of Fluid Therapy, Formulations, Diluents, Ophthalmic, Respule and Irrigation Solutions, etc. The Company markets its products in India as well as in the international market. In India, it has pan India presence. In international market, it has distributors across 5 continents.

**Note-1:- SIGNIFICANT ACCOUNTING POLICIES**

**1.1 Basis of Preparation:**

These financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on accrual basis. These financial statements have been prepared to comply in all material aspects with the accounting standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended), specified under section 133 and other relevant provisions of the Companies Act, 2013.

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division I) to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current – non-current classification of assets and liabilities.


**1.2. Use of Estimates:**

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognized in the periods in which the results are known/materialise.

**1.3 Property, Plant and Equipment and Depreciation/Amortization:**

**A. Tangible Assets:**

- i. Tangible Assets are stated at cost, net of accumulated depreciation. Cost comprises of the purchase price, non-refundable taxes and directly attributable expenses incurred to bring the asset to the location and condition necessary for it to be capable of being operated in the manner intended by management. Subsequent costs related to an item of Property, Plant and Equipment are recognised in the carrying amount of the item if the recognition criteria are met.
- ii. Depreciable amount for assets is the cost of an asset, or other amount substituted for cost, less its estimated residual value. Depreciation for the asset purchased/sold during the period is proportionately charged. Depreciation on property, plant and equipment has been provided on the straight-line method as per the useful life prescribed in Schedule II to the Companies Act, 2013 except in respect of the following categories of assets, in whose case the life of the assets has been assessed as under based on technical advice, taking into account the nature of the asset, the estimated usage of the asset, the operating conditions of the asset, past history of replacement, anticipated technological changes and maintenance support, etc.:



| Particulars        | Useful life as per Management | Useful life as per Schedule II - Companies Act, 2013 |
|--------------------|-------------------------------|--|
| Office Equipments  | 5-10 years                    | 5 years  |
| Plant & Equipments | 10 - 25 years                 | 15 - 20 years  |

Based on the internal assessment and technical evaluation carried out by the Company and historical usage of assets; the management believes that the useful lives as given above best represents the period over which management expects to use these assets.

- iii. An item of Property, Plant and Equipment is derecognised on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising on derecognition is recognised in the Statement of Profit and Loss.
- iv. The useful life, residual value and the depreciation method are reviewed atleast at each financial year end. If the expectations differ from previous estimates, the changes are accounted for prospectively as a change in accounting estimate.

## B. Intangible Assets:

Intangible assets are stated at acquisition cost, net of accumulated amortization and accumulated impairment losses, if any. Intangible assets are amortised on a straight line basis over their estimated useful lives. A rebuttable presumption that the useful life of an intangible asset will not exceed ten years from the date when the asset is available for use is considered by the management. The amortisation period and the amortisation method are reviewed at least at each financial year end. If the expected useful life of the asset is significantly different from previous estimates, the amortisation period is changed accordingly.

Gains or losses arising from the retirement or disposal of an intangible asset are determined as the difference between the net disposal proceeds and the carrying amount of the asset and recognised as income or expense in the Statement of Profit and Loss. The estimated useful lives of intangible assets are as follows:

| Particulars | Useful life as per Management                      |
|-------------|--|
| Software    | 5 years or tenure of licenses, whichever is lower. |

### 1.4 Goodwill arising on Amalgamation:

The goodwill is amortised to the Statement of profit and loss on a systematic basis over a period of five years.

### 1.5 Inventories:


Inventories are valued at the lower of cost and net realisable value after providing for obsolescence and other losses, where considered necessary. Cost includes all charges in bringing the goods to the point of sale, transit insurance, receiving charges and other levies. Work-in-progress and finished goods include appropriate proportion of overheads.

The basis for determining cost for various categories of inventory is as follows:

- i. Raw Materials - on FIFO Basis
- ii. Packing Materials - on FIFO Basis
- iii. Work in Progress - At Absorption Cost
- iv. Finished Goods - At Absorption Cost

### 1.6 Revenue Recognition:

- i. Revenue from sale of products is recognised when the significant risks and rewards of ownership of goods is transferred to the customer.
- ii. Revenue from sale of services is recognized when services are rendered.





- ### 1.7 Investments:

### 1.8 Employee Benefits:



#### **1.10 Borrowing Cost:**

Borrowing costs include interest and amortisation of ancillary borrowing costs incurred. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan. Borrowing costs, allocated to and utilised for qualifying assets, pertaining to the period from commencement of activities relating to construction/development of the qualifying asset up to the date of capitalisation of such asset are added to the cost of the assets. Capitalisation of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted, if any.

#### **1.11 Operating leases:**

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the Statement of Profit and Loss on a straight-line basis over the period of the lease.

#### **1.12 Impairment:**

Assessment is done at each balance sheet date as to whether there is any indication that an asset (tangible and intangible) may be impaired. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. An asset or CGU whose carrying value exceeds its recoverable amount is considered impaired and is written down to its recoverable amount. Assessment is also done at each balance sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased. An impairment loss is reversed to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined if no impairment loss had previously been recognised.


#### **1.13 Current and Deferred Tax:**

Tax expense for the period, comprising current tax and deferred tax, are included in the determination of the net profit or loss for the period. Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the taxation laws prevailing in the respective jurisdictions.

Deferred tax is recognised on timing differences, being the differences between the taxable income and the accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is measured using the tax rates and the tax laws enacted or substantively enacted as at the reporting date. Deferred tax liabilities are recognised for all timing differences.

Deferred tax assets are recognised and carried forward only to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted by the Balance Sheet date. In situations, where the Company has unabsorbed depreciation or carry forward losses under tax laws, all deferred tax assets are recognised only to the extent that there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. At each Balance Sheet date, the Company re-assesses unrecognised deferred tax assets, if any.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liability on a net basis. Deferred tax assets and deferred tax liabilities are offset when there is a legally enforceable right to set off assets against liabilities representing current tax and where the deferred tax assets and the deferred tax liabilities relate to taxes on income levied by the same governing taxation laws.



Minimum Alternate Tax (MAT) credit is recognised as an asset only when and to the extent there is convincing evidence that the company will pay normal income tax during the specified period. Such asset is reviewed at each Balance Sheet date and the carrying amount of the MAT credit asset is written down to the extent there is no longer a convincing evidence to the effect that the Company will pay normal income tax during the specified period.

#### **1.14 Provisions and Contingencies:**

**Provisions:** Provisions are recognised when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance sheet date and are not discounted to its present value.

**Contingent Liabilities:** Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

#### **1.15 Cash and Cash Equivalents:**

Cash and cash equivalents include cash on hand, demand deposits with banks, other short-term highly liquid investments with original maturities of three months or less.

#### **1.16 Earnings per Share:**

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Earnings considered in ascertaining the Company's earnings per share is the net profit for the period after deducting preference dividends and any attributable tax thereto for the period. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

#### **1.17 Segment Reporting:**

In accordance with the requirements of Accounting Standard 17 - 'Segment Reporting', the Company has determined its business segment as 'Manufacturing and sale of pharmaceutical products'. There are no other primary reportable segments.

